510(k) Report

510(k) · Cleared

Cleared

Daylight

K233872510(k) TraditionalCleared Aug 30, 2024267-day reviewClass II21 CFR 882.5801

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Big Health, Inc. · SCP Computerized Behavioral Therapy Device For Anxiety Disorders

Cleared on Aug 30, 2024 as substantially equivalent to K191716 (Pear Therapeutics, Inc., 2020) after a 267-day review. Its family tree reaches back 2 generations to 2017.

Decided
Aug 30, 2024
Review
267 days
Class
Class II
Product code
SCP
Recalls
None
Predicates
1

Its longest line of descent runs back 2 generations to DEN160018 (2017). No later device cites it as a predicate yet.

DEN160018 · reSet · Pear Therapeutics, Inc. · 2017K191716 · Somryst · Pear Therapeutics, Inc. · 2020201620182020202220242026
  1. Root · 2 generations backDEN160018 reSetPear Therapeutics, Inc. · 2017
  2. 1 generation backK191716 SomrystPear Therapeutics, Inc. · 2020
  3. This deviceK233872 DaylightBig Health, Inc. · 2024
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−2DEN160018reSetPear Therapeutics, Inc.2017—
−1K191716SomrystPear Therapeutics, Inc.2020—
0 (this device)K233872DaylightBig Health, Inc.2024—
FIG. 1 — Lineage of K233872, 2017–2024Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in SCP? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

  • Candidate predicates for a device like this, rankedin the report
  • Recall history across each candidate’s familyin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K191716Somryst
Summary page 4
…Psychiatry Disorders (21 CFR 882.5801) Regulatory class: Class II (Special Controls) 510(k) Number: K191716 Product code: QVO 4. Device Description Daylight is a digital therapeutic designed to address the sy…
Pear Therapeutics, Inc.2020—

Also cleared against K191716: 2 other devices →

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 7 years and passes through 2 companies; a new generation was cleared every 4.4 years on median.
  • None of the 2 ancestors has a recall.
  • 2 other devices also cite its predicate K191716.

How does its category compare?

All SCP devices

SCP Computerized Behavioral Therapy Device For Anxiety Disorders: FDA decisions, review times, recalls and adverse event reports over 20 years. 2024, this device’s year, is highlighted.

FDA decisions per year · SCP

1in 2024

2024: 1
2007high 1 (2024) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · SCP

Too few SCP 510(k)s in any year since 2007 to give a median.

Recalls per year · SCP

No recall names SCP since 2007.

Adverse event reports per year · SCP

No MAUDE report names SCP since 2007.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20100—00
20110—00
20120—00
20130—00
20140—00
20150—00
20160—00
20170—00
20180—00
20190—00
20200—00
20210—00
20220—00
20230—00
20241—00
20250—00
20260—0—

What is it indicated for?

Daylight is a prescription device delivering Cognitive Behavioral Therapy and can be made available on the order of a licensed healthcare provider. Daylight is a digital therapeutic intended to treat generalized anxiety disorder (GAD) by improving a patient's GAD symptoms as an adjunct to usual care in patients aged 22 years and older.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K233872: Daylight.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 5, 2026. https://510kreport.com/device/K233872

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026